This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Over the last 3 decades, pulmonary rehabilitation (PR) has become an integral part of the management of COPD. Many other chronic respiratory diseases have similar systemic manifestations including skeletal muscle impairment, commonly through deconditioning, and may benefit from PR. However, whereas many programs may accept patients with other respiratory diseases, the program may need several adaptations to optimally manage patients. This article uses the examples of interstitial lung disease including idiopathic pulmonary fibrosis, bronchiectasis, pulmonary hypertension, post lung transplantation, and post-COVID condition to highlight exemplar clinical problems. In addition, the rationale and latest evidence for PR are described alongside the adaptations to the program, including education needs of the delivery team and close integrated care with the wider clinical team. Finally, future directions for clinical care and research are discussed.
- pulmonary rehabilitation
- bronchiectasis
- interstitial lung disease
- pulmonary hypertension
- transplantation
- Long COVD
Footnotes
- Correspondence: Rachael A Evans MBChB FRCP PhD. E-mail: re66{at}le.ac.uk
Dr Evans presented a version of this paper at the 60th Respiratory Care Journal Conference, Pulmonary Rehabilitation: Current Evidence and Future Directions, held June 22–23, 2023, in St. Petersburg, Florida.
Dr Evans discloses relationships with Genentech/Roche and Moderna.
- Copyright © 2024 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.